Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Sees Large Decline in Short Interest

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 305,750 shares, a decline of 71.1% from the December 31st total of 1,057,055 shares. Currently, 12.4% of the shares of the stock are sold short. Based on an average trading volume of 514,457 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 514,457 shares, the short-interest ratio is presently 0.6 days. Currently, 12.4% of the shares of the stock are sold short.

Insider Buying and Selling

In other Ekso Bionics news, CEO Scott G. Davis sold 23,315 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $111,912.00. Following the sale, the chief executive officer directly owned 78,777 shares of the company’s stock, valued at $378,129.60. The trade was a 22.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jerome Wong sold 11,288 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total transaction of $54,182.40. Following the transaction, the chief financial officer directly owned 26,009 shares in the company, valued at approximately $124,843.20. The trade was a 30.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Ekso Bionics

Several institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Ekso Bionics during the 3rd quarter worth about $57,000. Shay Capital LLC purchased a new stake in Ekso Bionics in the third quarter valued at approximately $67,000. Citadel Advisors LLC purchased a new stake in shares of Ekso Bionics in the 3rd quarter valued at about $198,000. Finally, Consolidated Portfolio Review Corp acquired a new stake in shares of Ekso Bionics during the third quarter worth about $333,000. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Stock Performance

Shares of NASDAQ:EKSO traded up $0.40 during midday trading on Wednesday, reaching $8.66. The company had a trading volume of 95,005 shares, compared to its average volume of 382,980. Ekso Bionics has a 52-week low of $2.73 and a 52-week high of $12.70. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.11. The company’s 50 day moving average price is $6.30 and its 200 day moving average price is $4.99. The stock has a market cap of $22.68 million, a P/E ratio of -1.52 and a beta of 0.71.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.45. The firm had revenue of $4.23 million for the quarter, compared to the consensus estimate of $4.16 million. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. As a group, sell-side analysts anticipate that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on EKSO shares. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. Wall Street Zen upgraded Ekso Bionics to a “hold” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.50.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.